AZD-0466 is under clinical development by AstraZeneca and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AZD-0466’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AZD-0466 is under development for the treatment of acute myeloid leukemia, relapsed/refractory (R/R) mantle cell lymphoma (MCL), R/R follicular lymphoma (FL) or marginal zone lymphoma (MZL) including splenic, nodal, and extranodal subtypes and R/R diffuse large B-cell lymphoma (DLBCL), multiple myeloma, myelodysplastic syndrome, B-cell acute lymphoblastic leukemia and acute myeloid leukemia. It is developed based on dendrimer drug delivery technology. It acts by targeting Bcl2/xL protein. The drug candidate is administered through intravenous route as a nanoparticle formulation. It is a new molecular entity (NME). It was under development for the treatment of acute lymphocytic leukemia, lymphoma, relapsed and refractory acute myeloid leukemia, myelodysplastic syndrome, solid tumor, small-cell lung cancer, chronic myelomonocytic leukemia (CMML), multiple myeloma (Kahler Disease)
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of AZD-0466’s drug-specific PTSR and LoA scores, buy the report here.